Serum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack
European Journal of Neurology · 2026
DOI: 10.1111/ene.70767 ↗At a glance
Journal article in European Journal of Neurology, 2026. Written by Manon Rival and 40 co-authors. Institution: IGF, Univ Montpellier, CNRS, Inserm, Montpellier, France. Major MEDLINE topics: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Aquaporin 4, Neuromyelitis Optica, Glial Fibrillary Acidic Protein. 41 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Novartis, Agence Nationale de la Recherche, Observatoire Français de la Sclérose en Plaques (OFSEP).
Abstract (original language)
Background
Serum neurofilament‐light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are associated with multiple sclerosis (MS) activity. This study aimed to identify patient‐ and disease‐level determinants of sNfL and sGFAP and to evaluate their ability to support differential diagnosis in neuromyelitis optica (NMO). Methods sNFL and sGFAP levels were measured in 640 patients from the OFSEP cohort (88 NMO spectrum disorder (NMOSD) with anti‐aquaporin‐4 antibodies [AQP4‐NMOSD], 28 double‐seronegative NMOSD [DN‐NMOSD], 61 myelin oligodendrocyte glycoprotein antibody–associated disease [MOGAD], 64 clinically isolated syndrome [CIS], 237 relapsing–remitting MS [RRMS], and 162 primary progressive MS [PPMS]). The association between log[sNFL] and log[sGFAP] and age, sex, time since relapse, EDSS, oligoclonal bands, and MRI characteristics was analyzed by multiple linear regression. The diagnostic performance of sNfL and sGFAP in discriminating between NMOSD and MS subgroups was evaluated using multivariable logistic regression and area under the curve (AUC).
Results
For each group, specific associations of sNFL and sGFAP levels with patient characteristics were observed. Clearest associations were observed in AQP4‐NMOSD patients. After a recent attack (≤ 90 days), multivariate analysis revealed that sGFAP and age discriminated AQP4‐NMOSD from MOGAD (AUC = 0.939 [0.910;0.982]), AQP4‐NMOSD and DN‐NMOSD from MOGAD (AUC = 0.863 [0.776;0.977]), and AQP4‐NMOSD from all other groups (AUC = 0.950 [0.918;0.987]). Diagnostic probability heatmaps based on sGFAP and age illustrate the probability of each diagnosis relative to others for bedside interpretation.
Conclusion
After an acute attack of NMOSD, risk score based on sGFAP and age may guide the management of patients before autoantibody status is available.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- IGF, Univ Montpellier, CNRS, Inserm, Montpellier, France.
- Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
- Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Hospices Civils de Lyon, Bron, France.
- INSERM 1028 et CNRS UMR 5292, Centre de Recherche en Neurosciences de Lyon, Observatoire Français de la Sclérose en Plaques, Lyon, France.
- EUGENE DEVIC EDMUS Foundation Against Multiple Sclerosis, State-Approved Foundation, Bron, France.
- Laboratoire de Biostatistique, Epidémiologie Clinique, Santé Publique Innovation et Méthodologie (BESPIM), CHU Nimes, Univ Montpellier, Nimes, France.
ORCID profiles: Fabien Rollot, Romain Casey, Romain Marignier, Sophie Trouillet-Assant, Guillaume Mathey, Elisabeth Maillart, Laure Michel, Aurélie Ruet, Xavier Ayrignac, Jonathan Ciron, Jérôme de Sèze, Arnaud Kwiatkowski, Caroline Papeix, Pierre Branger, Christine Lebrun-Frenay, Jean Pelletier, Olivier Casez, Alain Créange, Thomas David, Laurent Magy, Jean-Philippe Camdessanche, Inès Doghri, Amélie Dos Santos, Thibault Mura, Eric Thouvenot
Funding
- Novartis
- Agence Nationale de la Recherche
- Observatoire Français de la Sclérose en Plaques (OFSEP)
- Eugène Devic EDMUS Foundation against multiple sclerosis
Cite
APA
Rival, M., Rollot, F., Laurent-Chabalier, S., Casey, R., El Bahi, I., Brocard, G., Marignier, R., Trouillet-Assant, S., Vukusic, S., Fromont, A., Laplaud, D. A., Mathey, G., Maillart, E., Michel, L., Ruet, A., Labauge, P., Ayrignac, X., Zephir, H., Ciron, J., …, & OFSEP Group and NOMADMUS Investigators (2026). Serum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack. European Journal of Neurology. https://doi.org/10.1111/ene.70767
Vancouver
Rival M, Rollot F, Laurent-Chabalier S, Casey R, El Bahi I, Brocard G, et al. Serum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack. European Journal of Neurology. 2026. doi:10.1111/ene.70767
BibTeX
@article{Rival2026,
author = {Rival, Manon and Rollot, Fabien and Laurent-Chabalier, Sabine and Casey, Romain and El Bahi, Illiasse and Brocard, Guillaume and Marignier, Romain and Trouillet-Assant, Sophie and Vukusic, Sandra and Fromont, Agnès and Laplaud, David Axel and Mathey, Guillaume and Maillart, Elisabeth and Michel, Laure and Ruet, Aurélie and Labauge, Pierre and Ayrignac, Xavier and Zephir, Hélène and Ciron, Jonathan and de Sèze, Jérôme and Kwiatkowski, Arnaud and Papeix, Caroline and Branger, Pierre and Lebrun-Frenay, Christine and Berger, Eric and Clavelou, Pierre and Heinzlef, Olivier and Pelletier, Jean and Al-Khedr, Abdullatif and Casez, Olivier and Bourre, Bertrand and Créange, Alain and David, Thomas and Magy, Laurent and Camdessanche, Jean-Philippe and Doghri, Inès and Dos Santos, Amélie and Mura, Thibault and Agherbi, Hanane and Thouvenot, Eric and OFSEP Group and NOMADMUS Investigators, OFSEP Group and NOMADMUS Investigators},
title = {Serum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack},
journal = {European Journal of Neurology},
year = {2026},
doi = {10.1111/ene.70767}
}
EUVIMED